Taking a drug called evolocumab can lower the chance of having a first major heart problem by 25% in people at high risk who’ve never had a heart attack or stroke before.
Evidence from Studies
Supporting (4)
Community contributions welcome
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes
Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials.
Contradicting (2)
Community contributions welcome
Rationale and Design of the Effect of EVolocumab in PatiEntS at High CArdiovascuLar RIsk WithoUt Prior Myocardial Infarction or Stroke (VESALIUS-CV) Trial.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.